SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

NCT04889183 · Completed

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can reduce kidney-related protein loss in obese adults who do not have diabetes.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 125 people

Who can join Ages 18+ · all sexes

Timeline Started 2022-03 · est. completion 2024-05

Where 13 sites · Canada, Germany, Netherlands, Spain

What this study is testing ClinicalTrials.gov NCT04889183 ↗

Description as written by the study sponsor.

Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.

Treatments tested

Semaglutide Drug

Patients will be treated for 24 weeks with semaglutide 3.0 mlg/ml s.c. once weekly. The starting dose of semaglutide will be 0.24 mg per week subcutaneous injection with increasing doses at 4, 8, 12, and 16 weeks to 0.5, 1,0, 1.7 and 2.4 mg.
Placebo Drug

Patients will receive a matching placebo sc. once weekly during the treatment period of 24 weeks.

Main thing measured	Change from baseline to week 24 in urinary albumin:creatinine ratio (UACR)
Sponsor	University Medical Center Groningen
Conditions studied	Obesity, Albuminuria
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04889183 ↗